Good news! Jifan Biotechnology (Beijing) Co., Ltd. was awarded the title of "2021 GEI China Potential Unicorn Enterprise"

On December 23, 2022, the 2022 China Potential Unicorn Enterprise Report Conference jointly hosted by Great Wall Strategic Consulting and the Suzhou Industrial Park Management Committee was held online, and Jifan Biotechnology (Beijing) Co., Ltd. was successfully selected into the "2021 China Potential Unicorn List".



Potential unicorn companies in China are playing an increasingly important role in leading new tracks, promoting high-quality regional economic development, and promoting the transformation of old and new driving forces. The selected enterprises are supported by technological innovation and professional skills, gradually becoming the main force in the wave of innovation and entrepreneurship, and are increasingly valued by the government and investors, becoming an important indicator to measure the level of innovation and development of an enterprise.



About potential unicorns
Potential unicorns refer to enterprises that have the potential to become unicorn enterprises based on their entrepreneurial teams, industry direction, technological innovation capabilities, and development trends.
GEI China Potential Unicorn Enterprise Standards: (1) Enterprises registered within China with legal personality; (2) Meet one of the following conditions: the post investment valuation of the last round of financing within 5 years of establishment reaches 100 million US dollars; The post investment valuation of the last round of financing from 5 to 9 years after its establishment reached $500 million; (3) Received private equity investment and has not yet been listed.


About Jifan Biotechnology (Beijing) Co., Ltd
Jifan Biotechnology (Beijing) Co., Ltd. is a national high-tech enterprise that integrates research and development, production, sales, and technical services. It has completed the industrial layout of nucleic acid, protein, instruments, materials, and consumables, and has multiple core technology platforms such as automated instruments, biological microspheres, nucleic acid purification, molecular enzymes, gene synthesis, antibody discovery, and protein purification, Committed to becoming a leading provider of life science tools and services. Since its establishment, the company has adhered to the direction of technological innovation and is committed to providing stable, reliable, cost-effective product solutions and professional technical services for scientific research, industrial medicine, and biopharmaceutical fields, achieving independent and controllable research and development and production of key raw materials.
Being selected as a potential unicorn enterprise is a witness to the company's practical and innovative approach in recent years, and will also urge the company to continue striving for excellence and progress, and continuously strive. As a reserve force for unicorn enterprises, the company will take this as a new starting point, adhering to the mission of "achieving a better life science", continue to focus on the upstream of the life science industry, develop high-quality, diverse, and stable performance products through technology platforms, and provide integrated solutions and technical services to create value for customers in fields such as IVD, biopharmaceuticals, and scientific research, striving to become a unicorn enterprise as soon as possible.